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replace the mitral valve with a mitral homograft in a
clinical situation6 was equally disappointing, and even-
tually the procedure was abandoned. In the present
decade, excellent long-term results of aortic homografts
and better understanding of mitral valve apparatus by
way of mitral valve repair have led to a revival of inter-
est in this procedure.7 However, apart from Acar and
colleagues,8-11 most of the investigators12-22 have
reported their experiences of limited numbers and
shorter durations. At our center, a mitral homograft was
first implanted in 1994,23,24 and early results were
reported.25 In this study we present our experience with
37 patients and a follow-up period of up to 60 months.
Methods
Patients. Thirty-seven patients (25 male subjects) aged 10
to 49 years (mean, 32 ± 10 years) with rheumatic mitral valve
disease underwent total (n = 35) or partial (n = 2) mitral valve
replacement with either a fresh antibiotic-preserved (n = 23)
S uccessful replacement of the diseased mitral valvewith a mitral homograft has remained a much-
desired target of cardiac surgeons. In the early 1960s, a
number of experimental studies1-5 were carried out to
determine the feasibility of such treatment. Most of
these studies, with few exceptions,1,2,4 demonstrated
early valve failure. The result of the first attempt to
Objective: Results of mitral valve replacement with a mitral homograft were
evaluated at 5 years to assess the suitability of the procedure.
Methods: Thirty-seven patients (25 male subjects) aged 10 to 49 years
(mean, 32 ± 10 years) with rheumatic mitral valve disease underwent total 
(n = 35) or partial (n = 2) mitral valve replacement with a fresh antibiotic-
preserved (n = 23) or cryopreserved (n = 14) mitral homograft. The pre-
dominant lesion was mitral stenosis (n = 30).
Results: There were 5 early deaths. Operative survivors were followed up for
1 to 60 months (mean, 26.6 ± 12 months). Among these, 21 patients had
severe mitral regurgitation during the follow-up period; 3 died and 8 under-
went reoperation. The homograft failure rate was not affected by preopera-
tive physiologic lesion (stenosis vs regurgitation, P = .4), type of homograft
(antibiotic-preserved vs cryopreserved homograft, P = .9), papillary muscle
pretreatment (yes vs no, P = .9), or addition of posterior collar annuloplasty
(yes vs no, P = .2). Among the remaining patients, 5 had moderate mitral
regurgitation, 4 had either trivial or mild mitral regurgitation, and 2 were lost
to follow-up. Study of the explanted mitral homografts (n = 8) revealed that
disruption of one of the donor papillary muscles was responsible for early
failures (n = 2), whereas cuspal and chordal degeneration was responsible for
late failures (n = 6). Microscopically, the explanted valve lacked any viable
cellular elements, and there was no evidence of immunologic injury to the
homografts.
Conclusion: The mitral homograft did not fulfill our expectations as a suit-
able substitute for the diseased mitral valve. (J Thorac Cardiovasc Surg
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or cryopreserved (n = 14) mitral homograft. The predominant
lesion was severe mitral stenosis (n = 30). Seven patients had
either associated moderate mitral regurgitation or isolated
severe mitral regurgitation. Four patients had associated tri-
cuspid valve disease, and one had significant aortic valve dis-
ease. Previous procedures included closed mitral valvotomy
(n = 3), balloon mitral valvotomy (n = 2), mitral valve repair
(n = 1), and the Ross procedure plus mitral valve repair (n =
1). Preoperatively, electrocardiography showed sinus rhythm
in 22 patients and atrial fibrillation in 15 patients. All patients
were in New York Heart Association class III or IV preoper-
atively.
All patients underwent preoperative transthoracic echocar-
diography and intraoperative transesophageal echocardiogra-
phy. Transesophageal echocardiography was used to assess
the valve morphology, the size of the mitral anulus, and the
need for partial or total homograft replacement.
Homograft procurement and storage. For donor selec-
tion, procurement, sterilization, and preservation, the recom-
mendations of the American Association of Tissue Banks26
were followed and were reported by us earlier.27 The donor
age ranged from 18 to 47 years, and the hearts were obtained
at autopsy within 24 hours of death. The entire mitral valve
apparatus, including the myocardium giving origin to papil-
lary muscles, was harvested. According to morphology and
papillary muscle arrangement, the mitral homografts were
classified into 3 types: type 1, good-sized anterior and poste-
rior cusps with chordae separated into 4 or fewer papillary
muscle heads; type 2, good-sized anterior and posterior cusps
with chordae separated into 5 or more papillary muscle
heads; and type 3, small, redundant, or damaged anterior and
posterior cusps.
Only type 1 homografts were preserved for further use. The
anulus of the graft was sized with circular valve obturators.
The height of the anterior mitral valve leaflet in its midpor-
tion was also measured.
The harvested grafts were kept in tissue culture medium
enriched with antibiotics (cefoxitin, lincomycin, polymyxin
B, vancomycin, and amphotericin B) for 48 hours at 4°C. In
our initial experience, antibiotic-preserved homografts (n =
23) were used directly within 40 days. Later on, the homo-
grafts were cryopreserved in Rosewell Park Memorial
Institute tissue culture medium No. 1640 with 10% fetal
calf serum amended with dimethylsulfoxide to a 10% con-
centration.
Surgical techniques
Homograft preparation. On the basis of intraoperative
transesophageal echocardiographic measurements of the
native anulus, 2 homografts with slightly larger measure-
ments were selected. Blood group compatibility was not
considered. At the time of implantation, excessive atrial
wall, fat, and ventricular muscles were excised, and the pap-
illary muscles were divided 12 to 15 mm beyond the origin
of the chordae.
Papillary muscle pretreatment. In the initial 25 patients the
papillary muscles were treated with 0.625% glutaraldehyde
solution for 20 minutes to make the papillary muscles firm
and easier to handle. A 3-mm, broad, glutaraldehyde-treated
strip of autologous pericardium was passed over the papillary
muscle heads between the chordae as a sling and sutured
below the muscle by means of 2 horizontal mattress sutures
with 5-0 polypropylene sutures.23 In the later 12 patients, pre-
treatment of donor papillary muscles with glutaraldehyde and
use of the pericardial sling were omitted.
Technique of homograft insertion. The mitral valve was
approached by a standard cardiopulmonary bypass technique.
The diseased mitral valve was excised, dividing the chordal
attachments at their insertion to papillary muscles. A stay
suture was passed through each of the papillary muscles and
was gently pulled out. The papillary muscles were mobilized
by dividing the muscular bands and attaching them to the
ventricular wall. After the homograft had been properly ori-
ented, 2 rows of horizontal mattress sutures (5-0 polypropy-
lene sutures) were passed through the native and donor pap-
illary muscles, ensuring that the donor and the native
papillary muscle tips were at the same level. The recipient
and donor papillary muscles were grouped in 4 heads. After
placement of all 8 sutures, the homograft was lowered into
the ventricular cavity and the sutures were tied. In this man-
ner, each donor papillary muscle was inserted into the slit
between the native papillary muscle and the wall of the ven-
tricle. In the patients in whom pericardial slings were not
constructed for homograft papillary muscles, pericardial
pledgets were used for suturing.
Subsequently, the cuspal tissue was sutured to the native
anulus with continuous 5-0 polypropylene sutures. In the ini-
tial 25 patients this suture line was buttressed with a 3-mm
broad strip of glutaraldehyde-treated autologous pericardium.
After completion of implantation, the valve was tested by
infusion of saline solution under pressure into the ventricle. If
the preoperative lesion was predominantly mitral regurgita-
tion with associated annular dilatation, a posterior collar
annuloplasty28 was performed. Annuloplasty was required in
7 of the initial 25 patients but was performed routinely in all
12 of the later patients.
After completion of the procedure, the function of the graft
was again assessed by transesophageal echocardiography.
Associated procedures. An associated procedure was per-
formed in 9 patients and included the modified De Vega tri-
cuspid repair (n = 4), removal of left atrial thrombus (n = 3),
and repair of left ventricular aneurysm (n = 1). One patient
underwent the Ross procedure for aortic valve disease and
modified De Vega repair for tricuspid regurgitation.
Postoperative echocardiographic evaluation. A transtho-
racic echocardiographic evaluation was performed before
discharge from the hospital, usually 4 to 7 days postopera-
tively and subsequently at 1, 3, and 6 months and every 6
months.
Statistical methods. Continuous or interval-related vari-
ables were expressed as means ± SD. Categoric variables
were expressed as percentages. Actuarial estimates were cal-
culated by the Kaplan-Meier technique29 and are reported
with the SE of the estimate. Prognostic factors for late failure
were analyzed by the Cox proportional hazard model. These
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factors included predominant lesion (mitral stenosis vs
other), previous cardiac procedure, type of homograft (antibi-
otic preserved vs cryopreserved), papillary muscle pretreat-
ment, and use of annuloplasty. All statistical analyses were
performed with the SPSS for Windows 6.0 software package
(SPSS Inc, Chicago, Ill).
Results
Early results. All patients survived the operation.
Mean cardiopulmonary bypass and aortic crossclamp
times were 127 ± 16 and 113 ± 17 minutes, respective-
ly. Two patients required inotropic support during
weaning from cardiopulmonary bypass. Both these
patients had left ventricular dysfunction preoperatively.
There were 5 hospital deaths. The cause of death
included severe acute mitral regurgitation caused by
papillary muscle rupture (n = 1), low cardiac output
syndrome (n = 2), septicemia (n = 1), and pulmonary
thromboembolism (n = 1). All other patients had
uneventful postoperative courses and were discharged
from the hospital after an interval of 7 to 10 days.
Intraoperative transesophageal echocardiography
confirmed trivial or no mitral regurgitation in all
patients. Echocardiographic evaluation before the dis-
charge showed no regurgitation or trivial mitral regur-
gitation in 18 patients, mild mitral regurgitation in 13
patients, and moderate mitral regurgitation in 1 patient.
The mitral valve area ranged from 3.0 to 4.2 cm2.
Late results. Follow-up ranged from 1 to 60 months
(mean, 26.6 ± 12 months). Two patients were lost to
follow-up.
Late deaths. There were 3 late deaths. All deaths
resulted from severe mitral regurgitation caused by
homograft failure. In 1 patient, 2 months postopera-
tively, 1 of the papillary muscles ruptured from its
attachment, resulting in severe acute mitral regurgita-
tion and death. Another patient, who had undergone
replacement of anterior leaflet only, had severe mitral
regurgitation caused by leaflet prolapse and died after
3 months. One patient who had moderate mitral regur-
gitation at the time of discharge had severe regurgita-
tion over a period of 6 months and died.
Reoperation. Eight patients underwent reoperation
for severe mitral regurgitation after an interval ranging
from 6 weeks to 58 months (Table I). Donor papillary
muscle disruption was responsible for early failures (n
= 2), whereas cusp-related pathology was primarily
responsible for late failures (n = 6). In all patients, the
homograft was replaced with a St Jude Medical mitral
prosthesis (St Jude Medical, Inc, St Paul, Minn). All
these patients survived reoperation.
Homograft function. Transthoracic echocardiography
revealed progressively increasing mitral regurgitation
in the majority of patients. Gradually, the proportion of
patients with trivial or mild regurgitation decreased,
whereas the proportion of patients with severe mitral
regurgitation increased (Fig 1). During the follow-up
period (1-60 months), 21 patients had severe mitral
regurgitation. The probability of normal homograft
function without significant regurgitation reached zero
at 54 months (Fig 2). The homograft failure rate was
not affected by preoperative physiologic lesion (steno-
Table I. Profile of patients requiring reoperation
Subject Age Glutaraldehyde 
No. (y) Sex Homograft pretreatment* Annuloplasty Interval† Mechanism of mitral regurgitation
1 21 M Antibiotic preserved + – 10 wk Rupture of donor papillary muscle to anterior
mitral leaflet
2 32 M Antibiotic preserved + – 6 wk Rupture of donor papillary muscle to anterior
mitral leaflet
3 23 M Antibiotic preserved + – 12 mo Rupture of strut chorda to anterior mitral leaflet
4 26 M Antibiotic preserved + – 49 mo Shrunken, retracted, prolapsing cusp calcification
in smooth part of anterior mitral leaflet
5 36 M Antibiotic preserved + + 52 mo Shrunken, retracted cusp chorda to anterior
mitral leaflet ruptured
6 45 M Cryopreserved – + 8 mo Circumferential tear in anterior mitral leaflet near
the anulus, small retracted cusp
7 31 M Cryopreserved – + 18 mo Shrunken, retracted cusps; incomplete coaptation
calcification of anterior mitral leaflet near the
anulus
8 12 M Antibiotic preserved + – 58 mo Heavily calcified anterior and posterior cusps,
incomplete coaptation
*Glutaraldehyde pretreatment of donor papillary muscles.
†Interval between initial operation and reoperation.
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sis vs regurgitation, P = .4), type of homograft (antibi-
otic-preserved vs cryopreserved, P = .9), papillary mus-
cle pretreatment (yes vs no, P = .9), or addition of pos-
terior collar annuloplasty (yes vs no, P = .2). Among
the patients with severe mitral regurgitation, 8 under-
went reoperation, 3 died, and 10 are awaiting reopera-
tion. Among the remaining 9 patients, 5 patients have
moderate mitral regurgitation. Only 4 patients with a
follow-up of 12 to 48 months showed either trivial or
mild mitral regurgitation.
Pathology of explanted valves
Macroscopic. Macroscopic pathology is shown in
Figs 3 to 7. In 2 patients (patients 1 and 2, Table I), the
valves were explanted after an interval of 10 and 6
weeks, respectively. In both patients the explanted
valve appeared normal on gross examination. One of
the 4 papillary muscle heads was ruptured in both
cases, with resultant flail anterior mitral leaflet. The
remaining donor-recipient papillary muscle junctions
appeared well healed. In the remaining patients the
valve cusps appeared thick, opaque, and retracted, with
intervening thin areas. One patient had a 3-mm hole in
the anterior mitral leaflet, and there was a circumferen-
tial tear in the anterior leaflet near the anulus (patient 6,
Table I). Two patients (patients 4 and 7, Table I) had
nodular calcification in the smooth part of the anterior
mitral leaflet. In 1 patient (patient 8, Table I) who
underwent homograft mitral valve replacement at the
age of 12 years, the homograft leaflets were extensive-
ly calcified (Fig 7) and failed to coapt.
The chordae were thinned in 2 patients (patients 3
and 5, Table I), and 1 of the strut chordae was ruptured
in each case. In 4 patients the chordae appeared to be
somewhat thicker than normal chordae. In 1 of the
patients (patient 4, Table I), the chordae were elongat-
ed, resulting in cusp prolapse. The papillary muscles
were fibrotic and calcified. There was firm union
between donor and recipient papillary muscles.
Microscopic. Microscopic pathology is shown in Figs
8 and 9. Six explanted mitral homografts (patients 3 to 8,
Table I) were available for histopathologic examination.
The details of microscopic findings are shown in Table
II. On light microscopic examination, there was com-
plete loss of endothelial lining of the cusps and chordae.
The valve leaflets were composed of anucleated struc-
tures because most of the mesenchymal components
lacked nuclei. The leaflets thus appeared to have only the
collagenous skeleton without any viable cells. In 4
Fig 1. Proportion of patients with either trivial-mild or severe
mitral regurgitation (MR). With increasing follow-up, almost
all the patients had severe mitral regurgitation.
Fig 2. The probability of normal homograft function
(Kaplan-Meier) during the follow-up period. MR, Mitral
regurgitation.
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valves, the valve leaflets had dystrophic calcification.
None of these valves showed neovascularization or
inflammatory infiltrate in the leaflets.
On examination of the subvalvular apparatus, the
chordae tendineae revealed similar loss of nucleated
cells with preservation of the collagenous tissue. The
endocardium overlying the papillary muscles was
thickened. In 3 patients (patients 3, 5, and 7, Table I)
the donor papillary muscle showed marked myocyte
degeneration, with a loss of nuclei and calcification.
There was no inflammatory infiltrate within the degen-
erated myocytes. However, at the periphery, focal for-
eign body giant cell reaction was noted in all 3 patients.
All 3 patients had focal fibrosis near the base of the
papillary muscles. The remaining 2 patients (patients 4
and 6, Table I) showed replacement fibrosis within the
papillary muscles. In 1 patient the subvalvular appara-
tus was not available for histologic evaluation.
Fig 3. Explanted mitral homograft 6 weeks after initial oper-
ation (patient 2, Table I). One of the donor papillary muscle
heads to the anterior mitral leaflet is ruptured. Remaining
donor-recipient papillary muscle junctions appear to be
healed.
Fig 4. Mitral homograft explanted 12 months after initial
operations (patient 3, Table I). One of the strut chordae to the
anterior mitral leaflet is ruptured (arrow)
Fig 5. Mitral homograft explanted 49 months after initial
operation. The cusp is small and retracted, with nodular cal-
cification (arrowhead) in its smooth part.
Fig 6. The explanted mitral homograft 18 months after initial
operation (patient 7, Table I). The cusps are retracted with
incomplete coaptation.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 120, Number 3
Kumar et al 455
Discussion
Earlier experimental studies1-5 and rare clinical tri-
als6,30 witnessed failure of the mitral homograft in
most of the cases. The earlier clinical failures were
attributed to inadequate valvular tissue conservation
and technical difficulties.6,8,30 Only after publication
of excellent results by Acar and colleagues10,11 did the
mitral homograft appear to be a suitable substitute for
the diseased mitral valve. Besides extensive experi-
ence with mitral valve repair, Acar and colleagues10
find two other factors as important contributors to the
excellent results. These factors include the side-by-
side suture technique for papillary muscle implanta-
tion and appropriate matching between the homograft
and the native valve.
We started our mitral homograft program in 1994,23,24
and the early and intermediate-term results appeared
satisfactory.25 Our technique of valve implantation was
similar to that of Acar and colleagues,8-10 with few dif-
ferences. In the initial part of our experience, we carried
out pretreatment of the papillary muscle with glu-
taraldehyde and autologous pericardium.23-25 After ini-
tial failures (rupture of donor papillary muscles in 3
patients), we abandoned the pretreatment and sutured
the papillary muscles directly. This helped us to achieve
a more secure donor-recipient papillary muscle union
because no papillary muscle disruption was noticed in
the next 12 patients.
An additional issue was that of the size of the mitral
homograft and the native mitral valve. We placed great
reliance on the anteroposterior diameter of the homo-
graft and the native valve anulus. Because most of our
patients had severe mitral stenosis with significant sub-
valvular fusion, measurement of chordal length as a
reference was not helpful. In most of our patients, the
ventricular cavity was either of normal size or slightly
smaller, and thus the homografts obtained from normal
hearts were considered to be of adequate height. With
this approach, we did not have any problem because
good valve function could be demonstrated in the
immediate and early postoperative periods by means of
transesophageal echocardiography.
Fig 7. The heavily calcified mitral homograft explanted from
a patient who received the homograft at the age of 12 years
(patient 8, Table I).
Fig 8. Photomicrograph from the explanted homograft mitral
valve leaflet showing paucity of nucleated cells within the
valve substance. The leaflet thus lacks viable cellular compo-
nent and it essentially represents fibrous skeleton.
(Hematoxylin and eosin stain; original magnification 90×.)
Fig 9. Representative area from the papillary muscle showing
thickened endocardium (E). The underlying myocytes (M)
are necrotic. (Hematoxylin and eosin stain; original magnifi-
cation 140×.)
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With the exception of few early failures, a reliable
and reproducible technique of homograft implantation
evolved. The early failures were overcome. The imme-
diate and early results proved to be satisfactory, but the
long-term results proved disappointing. In due time,
most of the homografts showed evidence of functional
failure (Figs 1 and 2). The homograft failure rate was
not affected by preoperative physiologic lesion, type of
homograft (antibiotic-preserved vs cryopreserved),
papillary muscle treatment, or addition of posterior col-
lar annuloplasty.
Explanted valves in our series showed cellular
autolysis and severe degeneration with loss of
endothelial and interstitial cells. Those were unlikely
to have any capacity to grow, remodel, or exhibit a
reparative process. The durability of valves appeared
to be largely related to the preserved extracellular
matrix. Similar changes were observed by other
investigators in explanted mitral homografts in
experimental studies.4,20 It is possible that because of
a lack of viable cells, as a result of preharvest
ischemia and cryopreservation,31,32 the valve is
unable to grow and remodel itself, and ultimately it
succumbs to degenerative changes. However, similar
absence of viable cells is also seen in explanted aor-
tic homografts, and thus the presence of viable cells
is not considered mandatory for long-term function
of aortic homograft.33,34 Then why should only the
mitral homograft fail? We have had satisfactory
results with aortic homografts harvested and implant-
ed under identical circumstances.35 Tamurak and col-
leagues20 have postulated that the arrangement of
connective tissue in the aortic valve makes it more
resistant to damage by mechanical forces. The pres-
ence of chordae and their attachments is an addition-
al factor that increases the susceptibility of the mitral
valve to damaging mechanical forces.20
Another important feature at histologic examination of
the explanted homografts was characteristic absence of
inflammatory infiltrates in the valve cusp and subvalvu-
lar apparatus. This suggests the absence of a cell-medi-
ated immunologic response to implanted homografts;
however, a humoral response cannot be ruled out.
The use of the mitral homograft in children deserves
a special comment. One of our patients who received a
mitral homograft at the age of 12 years (patient 8, Table
I) showed extensive calcification of the homograft at
reoperation (Fig 7). This suggests that, similar to bio-
prostheses, homografts are also susceptible to calcific
degeneration in younger patients.
In contrast to our experience, Acar and colleagues10
have reported excellent long-term results. Several fac-
tors may have contributed to this difference. First, all
our donors were cadaveric donors with preharvest
ischemic times ranging up to 24 hours, whereas in
Acar’s experience, homografts were obtained from
hearts explanted at the time of cardiac transplant, and
thus there was no preharvest ischemia. Second, our
homografts underwent antibiotic pretreatment, which
may have contributed to the decreased viability of cells.
Furthermore, about 40% of the patients in Acar’s expe-
rience had nonrheumatic etiology, and nearly 50% of
all the patients received a partial homograft. Contrary
to this, all our patients had rheumatic etiology, and only
2 patients received a partial homograft.
To conclude, the mitral homograft did not fulfill our
expectations, and we do not recommend its routine use
as a substitute for the diseased mitral valve.
Table II. Microscopic features of explanted mitral homografts (n = 6)
Mitral valve leaflet and chordae tendineae
Reference No. Type of Nuclear details
(from Table I) homograft Endothelium of cells Calcification Vascularization Inflammation
3 Antibiotic preserved Denuded Lost Nil Nil Nil
4 Antibiotic preserved Denuded Lost Present Nil Nil
5 Antibiotic preserved Denuded Lost Nil Nil Nil
6 Cryopreserved Denuded Lost Present Nil Nil
7 Cryopreserved Denuded Lost Present Nil Nil
8 Antibiotic preserved Denuded Lost Present Nil Nil
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